Navigation Menu
Jun 30, 2021 · The Journal of Cancer Science & Therapy is an academic journalhosted by OMICS Internationala pioneer in open access publishing–and is listed among the top 10 journals in hepatocellular carcinoma.
Jan 07, 2020 · Journal of Hepatocellular Carcinoma 2020, 7 . Published Date 9 November 2020. Original Research. Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.
11 hours ago · In contrast to several tumors whose prognoses are radically affected by novel immunotherapeutic approaches and/or targeted therapies, the outcomes of advanced hepatocellular carcinoma (HCC) remain poor. The underlying cirrhosis that is frequently associated with it complicates medical treatment and often determines survival. The landscape of HCC treatment had included
Jan 19, 2011 · Management of hepatocellular carcinoma An update. †. ‡. Jordi Bruix, Corresponding Author. [email protected] Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. fax (34) .
Hepatocellular cancer (HCC) is the fourth leading cause of cancer-related deaths worldwide and the fastest growing cause of cancer deaths in the United States. The overall prognosis of HCC remains dismal, except for the subset of patients who are diagnosed at early stage and receive potentially curative therapies, such as surgical resection and liver transplantation. Given this, expert society
Dec 15, 2014 · Most patients with hepatocellular carcinoma (HCC) have associated chronic liver disease, 1 usually at the stage of cirrhosis in which HCC development is one of the main causes of liver-related mortality. 2 It is widely perceived that survival in HCC depends on tumor stage, underlying liver function, and perhaps, performance status. Liver function is currently graded according to the Child
Immunotherapy in hepatocellular carcinoma the complex interface between inflammation, fibrosis, and the immune response Bridget P. Keenan , Lawrence Fong , Robin K. Kelley Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 267 DOI 10.1186/sz
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. HCC incidence rate is sixth and mortality is fourth worldwide. However, HCC pathogenesis and molecular
Feb 03, 2020 · Epidemiology of hepatocellular carcinoma in metabolic liver disease Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.
Apr 30, 2015 · The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. Lee HW, Lee HW, Lee JS, Roh YH, Lee H, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Journal of Hepatocellular Carcinoma 2021, 8 . Published Date 25 May 2021.
Feb 01, 2019 · Journal of Nuclear Medicine December 1, 2020, 61 (12) Prognostic Significance of 18 F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy A Multicenter Retrospective Cohort
Editor-in-Chief Dr. Ahmed Kaseb . Dr. Ahmed Kaseb is a Professor and Program Director of Hepatocellular Carcinoma (HCC), in the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Dr. Kaseb received his medical degree from Cairo University, and worked as a research fellow at University of Michigan, in Ann Arbor
Jan 01, 2000 · Primary hepatocellular carcinoma is one of the 10 most common tumours, and the most common primary liver malignancy, in the world. In the majority of cases, it occurs against a background of hepatitis B or C viral infection and/or liver cirrhosis, and is associated with a dismal prognosis of a few months. Current treatments in routine clinical practice are surgical resection and liver
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third cause of cancer-related mortality worldwide. Its incidence is clearly arising comprised by the prevalence of major risk factors mainly hepatitis B and hepatitis C. The population at risk is composed of chronic liver patients at the stage of extensive fibrosis or cirrhosis.
2019 Journal of Hepatocellular Carcinoma. Hepatocellular carcinoma (HCC) represents the second leading cause of cancer deaths worldwide and the main cause of death in patients with cirrhosis. Secondary prevention of HCC can be accomplished through the serial application of screening tests (ultrasound with or without alpha-fetoprotein) to
Hepatocellular carcinoma (HCC) is a major health problem worldwide. It is the fifth most common neoplasm in the world, with more than half million new cases yearly 1. The incidence of HCC rose in the last decade. In the USA, the incidence of HCC is expected to increase over the next two decades, equalling that currently experienced in Japan 2.
Feb 16, 2005 · Hepatocellular carcinoma (HCC) is one of the most common cancers in the world and is characterized by international variation in its distribution ( 1) these variations are related to the distribution of hepatitis C virus (HCV) and hepatitis B virus (HBV) infection.Chronic infection with HCV or HBV has been established as a major risk factor for HCC ( 2) .
Mar 03, 2021 · Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma. Ismail MS, Mohamed I, Polychronopoulou E, Goss JA, Kuo YF, Kanwal F, Jalal PK. Journal of Hepatocellular Carcinoma 2021, 8 . Published Date 29 June 2021.
Hepatocellular carcinoma (HCC) is the most common form of primary hepatic tumor and its incidence has increased in recent years.The risk factors for HCC are well established and include viral hepatitis, alcoholic liver cirrhosis, and exposure to hepatotoxins. The typical sonographic and unenhanced CT findings of HCC show a well-circumscribed hypoechoic or hypoattenuated mass with or without
Cytogenetics of hepatocellular carcinoma and adenoma have revealed gains of chromosome 1q as a significant differentiating factor. However, no studies are available comparing these amplification
Cytogenetics of hepatocellular carcinoma and adenoma have revealed gains of chromosome 1q as a significant differentiating factor. However, no studies are available comparing these amplification
Hepatitis B virus (HBV) risk and hepatocellular carcinoma (HCC) Epidemiology. It is estimated that over 50% of HCC cases worldwide are related to chronic HBV (1,2).Since the implementation of worldwide HBV vaccination there has been an overall decline in the burden of HBV, yet the HBV burden remains quite high in various parts of the world.
Feb 13, 2020 · Objective Hepatocellular carcinoma (HCC) has become a pressing health problem facing the world today due to its high morbidity, high mortality, and late discovery. As a diagnostic criteria of HCC, the exact threshold of Alpha-fetoprotein (AFP) is controversial. Therefore, this study was aimed to systematically estimate the performance of AFP in diagnosing HCC and to clarify its optimal threshold.
Jun 18, 2020 · CT and MRI of the liver for hepatocellular carcinoma Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.
Nov 16, 2020 · There were approximately 670,000 new cases and 625,000 deaths worldwide due to hepatocellular carcinoma (HCC) in 2018. HCC comprises 75%-85% of primary liver cancer cases and is the fourth-leading cause of annual cancer deaths worldwide. 1 In the United States, it is estimated that liver cancer will account for approximately 42,810 new cases and approximately 30,160 deaths in
Oct 26, 2016 · We congratulate Brown et al, 1 who performed a randomized trial to compare embolization using microspheres alone with chemoembolization using doxorubicin-loaded microspheres in patients with unresectable hepatocellular carcinoma (HCC). As they reminded us, the role of the chemotherapeutic agent in the efficacy of chemoembolization has been unclear for several decades.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, which in turns accounts for the sixth most common cancer worldwide. Despite being the 6 th most common cancer it is the second leading cause of cancer related deaths. HCC typically arises in the background of cirrhosis, however, about 20% of cases can develop in a
Aug 09, 2011 · Hepatocellular carcinoma (HCC) is the second most common cause of cancer death in men and the sixth in women worldwide (Jemal et al, 2011). Hepatocellular carcinoma is the most common tumour in
Apr 14, 2016 · Liver cancer is the second leading cause of cancer-related deaths globally and has an incidence of approximately 850,000 new cases per year. Hepatocellular carcinoma
Oct 26, 2016 · We congratulate Brown et al, 1 who performed a randomized trial to compare embolization using microspheres alone with chemoembolization using doxorubicin-loaded microspheres in patients with unresectable hepatocellular carcinoma (HCC). As they reminded us, the role of the chemotherapeutic agent in the efficacy of chemoembolization has been unclear for several decades.
Apr 01, 2018 · “A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma,” British Journal of Cancer
